You are here: Industry Insights > Amyris

News List

Amyris to buy women’s wellness firm MenoLabs pharmaceutical-business-review
January 25, 2022
Synthetic biotechnology company Amyris has agreed to acquire MenoLabs, a menopause symptoms treatment company.
ImmunityBio and Amyris conclude Covid-19 vaccine commercialisation JV Pharmaceutical-Technology
January 05, 2022
ImmunityBio and Amyris have concluded a joint venture (JV) agreement that was announced earlier to speed up the marketing of a next-generation vaccine for Covid-19.
Amyris, ImmunityBio Complete COVID-19 Vaccine Joint Venture contractpharma
January 03, 2022
Previously announced joint venture agreement accelerates commercialization of a next-generation COVID-19 vaccine.
Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine prnewswire
October 23, 2020
Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, announced the signing of a Collaboration Agreement and License Agreement ...
Amyris Announces Successful Closing of Secondary Offering firstwordpharma
August 22, 2018
EMERYVILLE, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) ("Amyris" or the "Company"), a leader in the development and production of sustainable ingredients for the Health & Wellness.....
Amyris Adds COO Role contractpharma
October 10, 2017
Eduardo Alvarez has been appointed chief operating officer, Amyris, Inc. This new position was created to support the company’s growth. Mr. Alvarez reports to John Melo, Amyris president and chief executive officer.
Amyris Names Kathleen Valiasek CFO contractpharma
January 09, 2017
Senior finance and business veteran with Fortune 500 experience joins company.